Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Notes Payables (2025)

Iovance Biotherapeutics (IOVA) has disclosed Notes Payables for 3 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables changed N/A to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a N/A change, with the full-year FY2025 number at $1.0 million, changed N/A from a year prior.
  • Notes Payables was $1.0 million for Q4 2025 at Iovance Biotherapeutics, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.0 million in Q1 2025 to a low of $1.0 million in Q1 2025.